Pegsunercept

From WikiProjectMed
Jump to navigation Jump to search
Pegsunercept
Clinical data
Routes of
administration
subcutaneous injection
ATC code
  • none
Legal status
Legal status
  • investigational
Pharmacokinetic data
BioavailabilityN/A
Identifiers
CAS Number
ChemSpider
  • none
UNII
KEGG
Chemical and physical data
FormulaC502H758N154O165S16
Molar mass12,103 g/mol (protein part) g·mol−1
 ☒NcheckY (what is this?)  (verify)

Pegsunercept is a drug for the treatment of rheumatoid arthritis. As of January 2010, Phase II clinical trials have been completed.[1][2][3] It is being developed by Amgen.

Similarly to etanercept, pegsunercept is a soluble tumor necrosis factor receptor. Pegsunercept is a PEGylated protein.[3]

References

  1. ^ Clinical trial number NCT00037700 for "Evaluation of the Efficacy of Combination Treatment With Anakinra and Pegsunercept in Improving Rheumatoid Arthritis" at ClinicalTrials.gov
  2. ^ Clinical trial number NCT00111423 for "Evaluating the Safety of Extended Treatment With Pegsunercept (PEG sTNF-RI)in Subjects With Rheumatoid Arthritis (RA)" at ClinicalTrials.gov
  3. ^ a b Furst DE, Fleischmann R, Kopp E, Schiff M, Edwards C, Solinger A, Macri M (December 2005). "A phase 2 dose-finding study of PEGylated recombinant methionyl human soluble tumor necrosis factor type I in patients with rheumatoid arthritis". The Journal of Rheumatology. 32 (12): 2303–10. PMID 16331754.